Natascha Roehlen1, Katharina Laubner2, Dominik Bettinger3, Henning Schwacha3, Hanna Hilger2, Carolin Koenig2, Dirk Grueninger4, Andreas Krebs4, Jochen Seufert2. 1. Department of Medicine II, Medical Center, Division of Endocrinology and Diabetology, Faculty of Medicine, University of Freiburg, Hugstetter Straße 55, 79106, Freiburg im Breisgau, Germany. natascha.roehlen@uniklinik-freiburg.de. 2. Department of Medicine II, Medical Center, Division of Endocrinology and Diabetology, Faculty of Medicine, University of Freiburg, Hugstetter Straße 55, 79106, Freiburg im Breisgau, Germany. 3. Department of Medicine II, Faculty of Medicine, Division of Hepatology, Gastroenterology and Gastrointestinal Endoscopy, University Hospital of Freiburg, Freiburg im Breisgau, Germany. 4. Centre of Laboratory Diagnostics, MVZ Clotten, Freiburg im Breisgau, Germany.
Abstract
BACKGROUND: The duodenal-jejunal bypass liner (DJBL) represents a novel endoscopic minimally invasive treatment option for obesity-associated type 2 diabetes (T2D), affecting body weight and metabolic control. Until now, the effects of DJBL on cardiovascular risk have never been investigated. METHODS: Between 2012 and 2017, 71 patients with T2D and metabolic syndrome (MS) were recruited for implantation of DJBL for 9-12 months. Within DJBL treatment and a follow-up period of 6 months, patients were analysed for dynamics of cardiovascular biomarkers. Overall cardiovascular risk was estimated by the ADVANCE Risk Engine at time of implantation, explantation and 6 months after explantation of DJBL. RESULTS: DJBL-induced weight loss and improvements in blood sugar control were accompanied by significant decreases of the cardiovascular biomarkers high-sensitive CRP, lipoprotein-associated phospholipase A2 and small dense lipoprotein fraction LDL-4 (p = 0.001, p < 0.001 and p = 0.04, respectively). Estimated overall cardiovascular risk decreased significantly after DJBL implantation and remained stable within 6 months after explantation. CONCLUSIONS: In addition to beneficial effects of DJBL on weight loss, glycaemic control and lipid parameters in patients with MS, this is the first study that could further reveal significant impact on serological cardiovascular biomarkers and estimated CV risk, suggesting putative protective effects of DJBL on CV outcome.
BACKGROUND: The duodenal-jejunal bypass liner (DJBL) represents a novel endoscopic minimally invasive treatment option for obesity-associated type 2 diabetes (T2D), affecting body weight and metabolic control. Until now, the effects of DJBL on cardiovascular risk have never been investigated. METHODS: Between 2012 and 2017, 71 patients with T2D and metabolic syndrome (MS) were recruited for implantation of DJBL for 9-12 months. Within DJBL treatment and a follow-up period of 6 months, patients were analysed for dynamics of cardiovascular biomarkers. Overall cardiovascular risk was estimated by the ADVANCE Risk Engine at time of implantation, explantation and 6 months after explantation of DJBL. RESULTS: DJBL-induced weight loss and improvements in blood sugar control were accompanied by significant decreases of the cardiovascular biomarkers high-sensitive CRP, lipoprotein-associated phospholipase A2 and small dense lipoprotein fraction LDL-4 (p = 0.001, p < 0.001 and p = 0.04, respectively). Estimated overall cardiovascular risk decreased significantly after DJBL implantation and remained stable within 6 months after explantation. CONCLUSIONS: In addition to beneficial effects of DJBL on weight loss, glycaemic control and lipid parameters in patients with MS, this is the first study that could further reveal significant impact on serological cardiovascular biomarkers and estimated CV risk, suggesting putative protective effects of DJBL on CV outcome.
Authors: Ron C Hoogeveen; John W Gaubatz; Wensheng Sun; Rhiannon C Dodge; Jacy R Crosby; Jennifer Jiang; David Couper; Salim S Virani; Sekar Kathiresan; Eric Boerwinkle; Christie M Ballantyne Journal: Arterioscler Thromb Vasc Biol Date: 2014-02-20 Impact factor: 8.311
Authors: Victoria Catalán; Javier Gómez-Ambrosi; Amaia Rodríguez; Camilo Silva; Fernando Rotellar; María J Gil; Javier A Cienfuegos; Javier Salvador; Gema Frühbeck Journal: Clin Endocrinol (Oxf) Date: 2007-09-04 Impact factor: 3.478
Authors: Ruben Schouten; Carianne S Rijs; Nicole D Bouvy; Wim Hameeteman; Ger H Koek; Ignace M C Janssen; Jan-Willem M Greve Journal: Ann Surg Date: 2010-02 Impact factor: 12.969
Authors: Francisco J Muruzábal; Gema Frühbeck; Javier Gómez-Ambrosi; Marta Archanco; María A Burrell Journal: Gen Comp Endocrinol Date: 2002-09 Impact factor: 2.822
Authors: Mira Katan; Yeseon P Moon; Myunghee C Paik; Robert L Wolfert; Ralph L Sacco; Mitchell S V Elkind Journal: PLoS One Date: 2014-01-09 Impact factor: 3.240
Authors: Thomas Karlas; David Petroff; Jürgen Feisthammel; Sebastian Beer; Matthias Blüher; Tatjana Schütz; Ralf Lichtinghagen; Albrecht Hoffmeister; Johannes Wiegand Journal: Obes Surg Date: 2022-06-17 Impact factor: 3.479
Authors: Andrea Telese; Vinay Sehgal; Cormac G Magee; S Naik; S A Alqahtani; L B Lovat; Rehan J Haidry Journal: Clin Transl Gastroenterol Date: 2021-06-18 Impact factor: 4.488